-
Biocon’s profitability to improve as structured equity exits ease interest burden: Kiran Mazumdar-Shaw
08 Aug 2025 19:30 GMT
… Shaw, Chairperson, Biocon Group
Pharma major Biocon Ltd. is … equity investments in Biocon and Biocon Biologics, which carried … profitability, both at Biocon Biologics and the consolidated … also optimistic about our cancer and immunology biosimilars portfolio …
-
Biocon Regulatory Approval Updates in the U.S. and Europe: Insulin Aspart and Denosumab
30 Jul 2025 17:48 GMT
… marks an important expansion of Biocon Biologics’s biosimilar insulin … on July 3, 2025, Biocon Biologics announced that the European … respectively.
The EC authorized Biocon Biologics’s VEVZUO for the … with advanced forms of bone cancers, and the treatment of …
-
Biocon Foundation and IISc on World Head & Neck Cancer Day called for oral cancer elimination
29 Jul 2025 12:09 GMT
… cancer elimination in India.
Dr Kiran Mazumdar-Shaw, chairperson, Biocon … in the Journal of Cancer Research Statistics and … said, "Globally, cancer claimed 9 million lives in … associated health risks like oral cancer.”
Prof Phaneendra Yalavarthy, …
-
Biocon Foundation and IISc Commemorate World Head & Neck Cancer Day
29 Jul 2025 08:57 GMT
… Biocon Foundation has driven an innovation- and research-led oral cancer … reduce late-stage oral cancer diagnoses. This collaborative effort … phonebased AI-enabled oral cancer screening tool has been … oral cancer elimination in India.
Shares of Biocon Limited …
-
Non-Small Cell Lung Cancer Market: Valued at $18.8 Billion in 2024, Expected to Grow at 6.9% CAGR Through 2035
15 Jul 2025 07:59 GMT
… • In April 2025, Biocon Biologics received FDA approval … cell lung cancer, metastatic colorectal cancer, metastatic renal … small cell lung cancer and pancreatic cancer.
• In …
• Multispeciality Hospitals
• Cancer Research Centers
Regional Analysis
…
-
Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States
15 Jul 2025 19:25 GMT
… Biosimilars Newco Limited, a Biocon Biologics Company.
Biocon Biologics & Logo are … /index.html About Biocon Biologics Limited: Biocon Biologics Limited, a subsidiary … for chronic conditions like diabetes, cancer and autoimmune. It has developed …
-
Ovarian Cancer Drugs Market to Hit $7.2 Billion by 2035, Driven by Rising FDA Approvals and 2024's $4.2 Billion Base
14 Jul 2025 07:02 GMT
… ovarian cancer (PROC).
Recent Developments
• In April 2025, Biocon Biologics … indicated for several cancers, including metastatic colorectal cancer, recurrent glioblastoma, … non-small cell lung cancer, advanced cervical cancer, and ovarian, fallopian …
-
EC approves Biocon Biologics’ denosumab biosimilars Vevzuo and Evfraxy
11 Jul 2025 11:55 GMT
… (EC) has approved Biocon Biologics’ biosimilars referencing Amgen’ … in adults with advanced cancer involving the bone, and … and survival of osteoclasts.
Biocon Biologics’ chief executive officer … after the EC approved Biocon Biologics’ Yesintek, an …
-
Two Biocon Biologics Denosumab Biosimilars Approved by MHRA
07 Jul 2025 18:58 GMT
… in men with prostate cancer or long-term systemic … (5).
References
1. Biocon Biologics. Biocon Biologics Receives MHRA UK … July 7, 2025.
2. Cancer Research UK. Denosumab Injection ( … Prolia, Xgeva). CancerResearchUK.org, Dec. 5, 2023 …
-
Cervical Cancer Treatment Market Size is Expected to Reach USD 14.91 Billion by 2030, with CAGR of 5.7%, Rising Prevalence of Cervical Cancer Fuels | The Insight Partners
07 Jul 2025 16:41 GMT
… ).
The treatment options for cervical cancer include surgery, radiation, chemotherapy, … with advanced or recurrent cervical cancer. Furthermore, advancements in diagnostic … Inc.; Amgen Inc.; Advaxis, Inc.; Biocon; Allergan, Inc.
Trending Topics: Squamous …
About
© 1995-2025